CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.22 USD | +6.09% |
|
+18.45% | -58.36% |
| Sales 2024 * | 15.52M 1.23B | Sales 2025 * | 7.2M 570M | Capitalization | 47.77M 3.79B |
|---|---|---|---|---|---|
| Net income 2024 * | -60M -4.75B | Net income 2025 * | -73M -5.78B | EV / Sales 2024 * | 3.08 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.64 x |
| P/E ratio 2024 * |
-0.91
x | P/E ratio 2025 * |
-0.92
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +6.09% | ||
| 1 week | +18.45% | ||
| Current month | -8.27% | ||
| 1 month | -9.63% | ||
| 3 months | -46.96% | ||
| 6 months | -60.65% | ||
| Current year | -58.36% |
1 week
1.00
1.31
1 month
0.991.35
Current year
0.993.06
1 year
0.999.77
3 years
0.999.77
5 years
0.999.77
10 years
0.999.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 31/12/15 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 31/01/18 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 31/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 31/01/18 |
Sanford Zweifach
CHM | Chairman | 68 | 31/10/21 |
| Director/Board Member | 66 | 31/01/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 32 M€ | +4.18% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/24 | 1.22 | +6.09% | 438,225 |
| 25/06/24 | 1.15 | +2.68% | 719,659 |
| 24/06/24 | 1.12 | +9.80% | 200,208 |
| 21/06/24 | 1.02 | +0.99% | 174,064 |
| 20/06/24 | 1.01 | -1.94% | 141,338 |
Delayed Quote Nasdaq, June 26, 2024 at 09:00 pm
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
09/07/2024
- Stifel Cell Therapy Forum
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.15
USD
Average target price
7.6
USD
Spread / Average Target
+560.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.36% | 47.77M | |
| +16.49% | 122B | |
| +21.73% | 116B | |
| +22.18% | 27.03B | |
| -21.81% | 20.36B | |
| -16.89% | 16.43B | |
| -18.81% | 15.91B | |
| -44.74% | 15.6B | |
| +62.72% | 14.94B | |
| +3.09% | 13.59B |
- Stock Market
- Equities
- CARM Stock
